Catalent.com Contact Us BIOLOGICS GENE THERAPY CELL THERAPY SPECIALTY TECHNOLOGIES EXPERT CONTENT ABOUT US CAREERS CATALENT COMPLETES ACQUISITION OF RHEINCELL THERAPEUTICS, STRENGTHENING A PATH TOWARDS INDUSTRIALIZATION OF IPSC-BASED THERAPIES Learn More 1234 HOW CAN WE WORK TOGETHER BIOLOGICS DEVELOPMENT GENE THERAPY CELL THERAPY TECHNOLOGIES LATEST NEWS Catalent Biologics Launches New GPEx® Lightning Cell Line Expression Technology to Shorten Drug Substance Development Timelines by up to Three Months CATALENT RESPONDS TO THE GLOBAL COVID-19 OUTBREAK We are taking decisive action to minimize the impact of the COVID-19 pandemic on our employees, partners, customers, and their patients. LEARN MORE CELL THERAPY With our advanced technologies and expertise in both autologous and allogeneic development and manufacturing, Catalent is your full-service partner for CAR-T immunotherapies and beyond. GENE THERAPY Our Gene Therapy team combines leading expertise in viral vector technology and scale-up with state-of-the-art CGMP facilities, including dedicated plasmid DNA manufacturing sites and our FDA approved commercial facility. STRATEGIES TO ACHIEVE SUCCESSFUL COMMERCIAL APPROVAL & LAUNCH Experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the successful launch and approval of a biologic. BIOLOGICS NETWORK Our network of biologics sites provides an integrated approach to get medicines to your patients faster anywhere in the world. LEARN MORE JOIN OUR TEAM Catalent is growing in Biologics and is making significant investments in people in this area. Explore global career opportunities with our Biologics team.</p> <p> NEWS Catalent’s Investment in Expanding its State-of-the-Art Gene Therapy Commercial Manufacturing Campus in Harmans, Maryland, Increases to $360M Catalent Biologics Launches New GPEx® Lightning Cell Line Expression Technology to Shorten Drug Substance Development Timelines by up to Three Months Catalent Plans Multi-Phase, $100 Million Expansion of Italian Facility to Increase Biologics Manufacturing Capabilities in Europe Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of Induced Pluripotent Stem Cell-based Therapies VIEW ALL NEWS EVENTS PEGS Europe 2021 CPhI Worldwide 2021 Strategies to Accelerate the Path to Clinic for Next-Generation Antibodies Pharma Manufacturing Europe VIEW ALL EVENTS EXPERT CONTENT Advances in Analytical Technology for Biopharmaceuticals Prefilled Syringes & Parenteral Manufacturing Accelerating Method Transfer: Effective Automation Of Biological Assays VIEW ALL ARTICLES Expert Content Subscribe Investors Contact Us Site Map Follow Us. Share Us. By using this website you understand and accept that Catalent tracks your website activities to be able to offer you a more tailored response or information to meet your requirements, and that your personal data will be held in accordance with our Privacy Policy | Privacy Shield Statement | Cookies Settings. Copyright 2021, Catalent, Inc - All Rights Reserved Terms Modern Slavery Statement This Website Uses Cookies By using this website you understand and accept that Catalent tracks your website activities to be able to offer you a more tailored response or information to meet your requirements, and that your personal data will be held in accordance with our Privacy Policy. Accept All Cookies Cookies Settings